Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2013

Open Access 01-12-2013 | Review

Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care

Authors: Amikar Sehdev, Daniel VT Catenacci

Published in: Journal of Hematology & Oncology | Issue 1/2013

Login to get access

Abstract

Gastroesophageal cancer (GEC) remains a challenging problem in oncology. Anatomically, GEC is comprised of distal gastric adenocarcinoma (GC), classically associated with Helicobacter Pylori, while proximal esophagogastric adenocarcinoma (EGJ AC) has increased significantly in incidence over the past years. Despite contrasting etiologies, histologies, and molecular phenotypes of distal and proximal GEC, in many cases perioperative (and metastatic) treatment strategies converge to similar approaches. For patients undergoing curative intent surgery, advances in perioperative chemotherapy and/or chemoradiotherapy, either before and/or after surgery, have demonstrated improved survivals compared to surgery alone. This review focuses on how the ‘boundary’ of the Z-line and/or the anatomical distinction of ‘proximal’ (EGJ) vs. ‘distal’ (GC) cancer has led to diverse inclusion/exclusion criteria for clinical trial enrollment, embodying various combinations of chemotherapy and radiation before and/or after surgery. Supporting evidence of each of these approaches consequently has led to a number of varying practices by geographical region and Institution/Physician, based on differing experience, preference, and clinical circumstance. Adequate direct comparison of these approaches is lacking currently, but data from a number of concerted efforts should be available in the next years to further direct best standards of care. Introduction of biologically targeted agents, namely anti-angiogenics and anti-HER family therapeutics are being evaluated to determine whether further therapeutic gains can be realized over classic cytotoxic chemotherapy alone (with/without radiotherapy). To date, novel molecularly targeted agents have yet to demonstrate benefit in this setting. In the following comprehensive review we will address the intricacies of perioperative treatment of locally advanced GEC, with focus on clinical trials supporting the diverse set of perioperative multidisciplinary approaches.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sehdev A, Catenacci DVT: Gastroesophageal cancer: focus on epidemiology, classification and staging. Discov Med. 2013, 16 (87): 103-111.PubMed Sehdev A, Catenacci DVT: Gastroesophageal cancer: focus on epidemiology, classification and staging. Discov Med. 2013, 16 (87): 103-111.PubMed
2.
go back to reference Konda VJ, Waxman I: Endotherapy for Barrett’s esophagus. Am J Gastroenterol. 2012, 107: 827-833. 10.1038/ajg.2012.70.CrossRefPubMed Konda VJ, Waxman I: Endotherapy for Barrett’s esophagus. Am J Gastroenterol. 2012, 107: 827-833. 10.1038/ajg.2012.70.CrossRefPubMed
3.
go back to reference Mariette C, Piessen G, Briez N, Gronnier C, Triboulet JP: Oesophagogastric junction adenocarcinoma: which therapeutic approach?. Lancet Oncol. 2011, 12: 296-305. 10.1016/S1470-2045(10)70125-X.CrossRefPubMed Mariette C, Piessen G, Briez N, Gronnier C, Triboulet JP: Oesophagogastric junction adenocarcinoma: which therapeutic approach?. Lancet Oncol. 2011, 12: 296-305. 10.1016/S1470-2045(10)70125-X.CrossRefPubMed
4.
go back to reference Noffsinger A, Waxman I: Preinvasive neoplasia in the stomach: diagnosis and treatment. Clin Gastroenterol Hepatol. 2007, 5: 1018-1023. 10.1016/j.cgh.2007.07.004.CrossRefPubMed Noffsinger A, Waxman I: Preinvasive neoplasia in the stomach: diagnosis and treatment. Clin Gastroenterol Hepatol. 2007, 5: 1018-1023. 10.1016/j.cgh.2007.07.004.CrossRefPubMed
5.
go back to reference Barreto JC, Posner MC: Transhiatal versus transthoracic esophagectomy for esophageal cancer. World J Gastroenterol. 2010, 16: 3804-3810. 10.3748/wjg.v16.i30.3804.PubMedCentralCrossRefPubMed Barreto JC, Posner MC: Transhiatal versus transthoracic esophagectomy for esophageal cancer. World J Gastroenterol. 2010, 16: 3804-3810. 10.3748/wjg.v16.i30.3804.PubMedCentralCrossRefPubMed
6.
go back to reference Posner MC: Cancer of the Upper Gastrointestinal Tract. Edited by: Posner M, Vokes EE, Weichselbaum RR. 2002, Ontario, Canada: B.C. Decker, Inc, 1 Posner MC: Cancer of the Upper Gastrointestinal Tract. Edited by: Posner M, Vokes EE, Weichselbaum RR. 2002, Ontario, Canada: B.C. Decker, Inc, 1
7.
go back to reference Feith M, Stein HJ, Siewert JR: Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients. Surg Oncol Clin N Am. 2006, 15: 751-764. 10.1016/j.soc.2006.07.015.CrossRefPubMed Feith M, Stein HJ, Siewert JR: Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients. Surg Oncol Clin N Am. 2006, 15: 751-764. 10.1016/j.soc.2006.07.015.CrossRefPubMed
8.
go back to reference Seevaratnam R, Bocicariu A, Cardoso R, Mahar A, Kiss A, Helyer L, Law C, Coburn N: A meta-analysis of D1 versus D2 lymph node dissection. Gastric Cancer. 2012, 15 (Suppl 1): S60-S69.CrossRefPubMed Seevaratnam R, Bocicariu A, Cardoso R, Mahar A, Kiss A, Helyer L, Law C, Coburn N: A meta-analysis of D1 versus D2 lymph node dissection. Gastric Cancer. 2012, 15 (Suppl 1): S60-S69.CrossRefPubMed
9.
go back to reference Roggin KK, Hemmerich J, Posner MC: Extended follow-up after extended lymphadenectomy for gastric cancer: was it worth the wait?. Lancet Oncol. 2010, 11: 404-405. 10.1016/S1470-2045(10)70098-X.CrossRefPubMed Roggin KK, Hemmerich J, Posner MC: Extended follow-up after extended lymphadenectomy for gastric cancer: was it worth the wait?. Lancet Oncol. 2010, 11: 404-405. 10.1016/S1470-2045(10)70098-X.CrossRefPubMed
10.
go back to reference Macdonald JS: Gastric cancer: Nagoya is not New York. J Clin Oncol. 2011, 29: 4348-4350. 10.1200/JCO.2011.37.5691.CrossRefPubMed Macdonald JS: Gastric cancer: Nagoya is not New York. J Clin Oncol. 2011, 29: 4348-4350. 10.1200/JCO.2011.37.5691.CrossRefPubMed
11.
go back to reference Shah MA, Ajani JA: Gastric cancer–an enigmatic and heterogeneous disease. JAMA. 2010, 303: 1753-1754. 10.1001/jama.2010.553.CrossRefPubMed Shah MA, Ajani JA: Gastric cancer–an enigmatic and heterogeneous disease. JAMA. 2010, 303: 1753-1754. 10.1001/jama.2010.553.CrossRefPubMed
12.
go back to reference Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996, 335: 462-467. 10.1056/NEJM199608153350702.CrossRefPubMed Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996, 335: 462-467. 10.1056/NEJM199608153350702.CrossRefPubMed
13.
go back to reference Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005, 6: 659-668. 10.1016/S1470-2045(05)70288-6.CrossRefPubMed Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005, 6: 659-668. 10.1016/S1470-2045(05)70288-6.CrossRefPubMed
14.
go back to reference Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008, 26: 1086-1092. 10.1200/JCO.2007.12.9593.CrossRefPubMed Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008, 26: 1086-1092. 10.1200/JCO.2007.12.9593.CrossRefPubMed
15.
go back to reference Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001, 19: 305-313.PubMed Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001, 19: 305-313.PubMed
16.
go back to reference Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007, 8: 226-234. 10.1016/S1470-2045(07)70039-6.CrossRefPubMed Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007, 8: 226-234. 10.1016/S1470-2045(07)70039-6.CrossRefPubMed
17.
go back to reference Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V, Australasian Gastro-Intestinal Trials G: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011, 12: 681-692. 10.1016/S1470-2045(11)70142-5.CrossRefPubMed Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V, Australasian Gastro-Intestinal Trials G: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011, 12: 681-692. 10.1016/S1470-2045(11)70142-5.CrossRefPubMed
18.
go back to reference van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012, 366: 2074-2084. 10.1056/NEJMoa1112088.CrossRefPubMed van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012, 366: 2074-2084. 10.1056/NEJMoa1112088.CrossRefPubMed
19.
go back to reference Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001, 345: 725-730. 10.1056/NEJMoa010187.CrossRefPubMed Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001, 345: 725-730. 10.1056/NEJMoa010187.CrossRefPubMed
20.
go back to reference Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM: Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012, 30: 2327-2333. 10.1200/JCO.2011.36.7136.PubMedCentralCrossRefPubMed Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM: Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012, 30: 2327-2333. 10.1200/JCO.2011.36.7136.PubMedCentralCrossRefPubMed
21.
go back to reference Brooks GA, Enzinger PC, Fuchs CS: Adjuvant therapy for gastric cancer: revisiting the past to clarify the future. J Clin Oncol. 2012, 30: 2297-2299. 10.1200/JCO.2012.42.4069.CrossRefPubMed Brooks GA, Enzinger PC, Fuchs CS: Adjuvant therapy for gastric cancer: revisiting the past to clarify the future. J Clin Oncol. 2012, 30: 2297-2299. 10.1200/JCO.2012.42.4069.CrossRefPubMed
22.
go back to reference Macdonald JS, Benedetti J, Smalley S, Haller D, Hundahl S, Jessup J, Ajani J, Gunderson L, Goldman B, Martenson J: Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008)[Abstract]. J Clin Oncol. 2009, 27: 15s-10.1200/JCO.2008.21.7695. suppl; abstr 4515CrossRef Macdonald JS, Benedetti J, Smalley S, Haller D, Hundahl S, Jessup J, Ajani J, Gunderson L, Goldman B, Martenson J: Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008)[Abstract]. J Clin Oncol. 2009, 27: 15s-10.1200/JCO.2008.21.7695. suppl; abstr 4515CrossRef
23.
go back to reference Kim S, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, Park SH, Lee SH, Kim K, Park JO: An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys. 2005, 63: 1279-1285. 10.1016/j.ijrobp.2005.05.005.CrossRefPubMed Kim S, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, Park SH, Lee SH, Kim K, Park JO: An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys. 2005, 63: 1279-1285. 10.1016/j.ijrobp.2005.05.005.CrossRefPubMed
24.
go back to reference Kim TH, Park SR, Ryu KW, Kim YW, Bae JM, Lee JH, Choi IJ, Kim YJ, Kim DY: Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys. 2012, 84: e585-e592. 10.1016/j.ijrobp.2012.07.2378.CrossRefPubMed Kim TH, Park SR, Ryu KW, Kim YW, Bae JM, Lee JH, Choi IJ, Kim YJ, Kim DY: Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys. 2012, 84: e585-e592. 10.1016/j.ijrobp.2012.07.2378.CrossRefPubMed
25.
go back to reference Costa WL, Coimbra FJ, Fogaroli RC, Ribeiro HS, Diniz AL, Begnami MD, Mello CA, Fanelli MF, Silva MJ, Fregnani JH, Montagnini AL: Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a single cancer center. Radiat Oncol. 2012, 7: 169-10.1186/1748-717X-7-169.PubMedCentralCrossRefPubMed Costa WL, Coimbra FJ, Fogaroli RC, Ribeiro HS, Diniz AL, Begnami MD, Mello CA, Fanelli MF, Silva MJ, Fregnani JH, Montagnini AL: Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a single cancer center. Radiat Oncol. 2012, 7: 169-10.1186/1748-717X-7-169.PubMedCentralCrossRefPubMed
26.
go back to reference Lee J, Lim Do H, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH: Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012, 30: 268-273. 10.1200/JCO.2011.39.1953.CrossRefPubMed Lee J, Lim Do H, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH: Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012, 30: 268-273. 10.1200/JCO.2011.39.1953.CrossRefPubMed
27.
go back to reference Group MRCOCW: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002, 359: 1727-1733.CrossRef Group MRCOCW: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002, 359: 1727-1733.CrossRef
28.
go back to reference Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J: Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European organisation for research and treatment of cancer randomized trial 40954. J Clin Oncol. 2010, 28: 5210-5218. 10.1200/JCO.2009.26.6114.PubMedCentralCrossRefPubMed Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J: Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European organisation for research and treatment of cancer randomized trial 40954. J Clin Oncol. 2010, 28: 5210-5218. 10.1200/JCO.2009.26.6114.PubMedCentralCrossRefPubMed
29.
go back to reference Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE: Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009, 27: 5062-5067. 10.1200/JCO.2009.22.2083.CrossRefPubMed Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE: Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009, 27: 5062-5067. 10.1200/JCO.2009.22.2083.CrossRefPubMed
31.
go back to reference Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007, 357: 1810-1820. 10.1056/NEJMoa072252.CrossRefPubMed Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007, 357: 1810-1820. 10.1056/NEJMoa072252.CrossRefPubMed
32.
go back to reference Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011, 29: 4387-4393. 10.1200/JCO.2011.36.5908.CrossRefPubMed Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011, 29: 4387-4393. 10.1200/JCO.2011.36.5908.CrossRefPubMed
33.
go back to reference Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M: Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010, 303: 1729-1737.CrossRefPubMed Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M: Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010, 303: 1729-1737.CrossRefPubMed
34.
go back to reference Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY: Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012, 379: 315-321. 10.1016/S0140-6736(11)61873-4.CrossRefPubMed Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY: Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012, 379: 315-321. 10.1016/S0140-6736(11)61873-4.CrossRefPubMed
36.
go back to reference Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998, 339: 1979-1984. 10.1056/NEJM199812313392704.CrossRefPubMed Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998, 339: 1979-1984. 10.1056/NEJM199812313392704.CrossRefPubMed
37.
go back to reference Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG: Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007, 25: 3719-3725. 10.1200/JCO.2006.10.4760.CrossRefPubMed Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG: Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007, 25: 3719-3725. 10.1200/JCO.2006.10.4760.CrossRefPubMed
38.
go back to reference Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006, 355: 11-20. 10.1056/NEJMoa055531.CrossRefPubMed Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006, 355: 11-20. 10.1056/NEJMoa055531.CrossRefPubMed
39.
go back to reference Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011, 29: 1715-1721. 10.1200/JCO.2010.33.0597.CrossRefPubMed Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011, 29: 1715-1721. 10.1200/JCO.2010.33.0597.CrossRefPubMed
40.
go back to reference Biffi R, Fazio N, Luca F, Chiappa A, Andreoni B, Zampino MG, Roth A, Schuller JC, Fiori G, Orsi F: Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World J Gastroenterol. 2010, 16: 868-874.PubMedCentralPubMed Biffi R, Fazio N, Luca F, Chiappa A, Andreoni B, Zampino MG, Roth A, Schuller JC, Fiori G, Orsi F: Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World J Gastroenterol. 2010, 16: 868-874.PubMedCentralPubMed
41.
go back to reference Ferri LE, Ades S, Alcindor T, Chasen M, Marcus V, Hickeson M, Artho G, Thirlwell MP: Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. Ann Oncol. 2012, 23: 1512-1517. 10.1093/annonc/mdr465.CrossRefPubMed Ferri LE, Ades S, Alcindor T, Chasen M, Marcus V, Hickeson M, Artho G, Thirlwell MP: Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. Ann Oncol. 2012, 23: 1512-1517. 10.1093/annonc/mdr465.CrossRefPubMed
42.
go back to reference Homann N, Pauligk C, Luley K, Werner Kraus T, Bruch HP, Atmaca A, Noack F, Altmannsberger HM, Jager E, Al-Batran SE: Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer. 2012, 130: 1706-1713. 10.1002/ijc.26180.CrossRefPubMed Homann N, Pauligk C, Luley K, Werner Kraus T, Bruch HP, Atmaca A, Noack F, Altmannsberger HM, Jager E, Al-Batran SE: Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer. 2012, 130: 1706-1713. 10.1002/ijc.26180.CrossRefPubMed
43.
go back to reference Bajetta E, Floriani I, Bartolomeo MD, Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer [Abstract]. J Clin Oncol. 2012, 30: suppl; abstr LBA4001 Bajetta E, Floriani I, Bartolomeo MD, Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer [Abstract]. J Clin Oncol. 2012, 30: suppl; abstr LBA4001
44.
go back to reference Kobayashi M, Tsuburaya A, Yoshida K, Yoshino S, Miyashita Y: Adjuvant paclitaxel followed by oral fluoropyrimidines for gastric cancer: Safety data of the factorial phase III SAMIT trial [Abstract]. J Clin Oncol. 2012, 30: suppl 4; abstr 72 Kobayashi M, Tsuburaya A, Yoshida K, Yoshino S, Miyashita Y: Adjuvant paclitaxel followed by oral fluoropyrimidines for gastric cancer: Safety data of the factorial phase III SAMIT trial [Abstract]. J Clin Oncol. 2012, 30: suppl 4; abstr 72
45.
go back to reference Yoshida K, Tsuburaya A, Kobayashi M, Yoshino S, Takahashi M, Takiguchi M, Tanabe K, Takahashi N: SAMIT: A phase III randomized clinical trial of adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer [Abstract]. J Clin Oncol. 2013, 31: suppl; abstr LBA4002 Yoshida K, Tsuburaya A, Kobayashi M, Yoshino S, Takahashi M, Takiguchi M, Tanabe K, Takahashi N: SAMIT: A phase III randomized clinical trial of adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer [Abstract]. J Clin Oncol. 2013, 31: suppl; abstr LBA4002
46.
go back to reference Fuchs CS, Tepper JE, Niedzwiecki D, Hollis D, Mamon HJ, Swanson R, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Enzinger PC, Goldberg RM, Venook AP, Mayer RJ: Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101 [Abstract]. J Clin Oncol. 2011, 29: suppl; abstr 4003 Fuchs CS, Tepper JE, Niedzwiecki D, Hollis D, Mamon HJ, Swanson R, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Enzinger PC, Goldberg RM, Venook AP, Mayer RJ: Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101 [Abstract]. J Clin Oncol. 2011, 29: suppl; abstr 4003
47.
go back to reference Sarkaria IS, Rizk NP, Bains MS, Tang LH, Ilson DH, Minsky BI, Rusch VW: Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg. 2009, 249: 764-767. 10.1097/SLA.0b013e3181a38e9e.CrossRefPubMed Sarkaria IS, Rizk NP, Bains MS, Tang LH, Ilson DH, Minsky BI, Rusch VW: Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg. 2009, 249: 764-767. 10.1097/SLA.0b013e3181a38e9e.CrossRefPubMed
48.
go back to reference Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschlager G, Busch R, Siewert JR, Schwaiger M, Fink U: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001, 19: 3058-3065.PubMed Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschlager G, Busch R, Siewert JR, Schwaiger M, Fink U: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001, 19: 3058-3065.PubMed
49.
go back to reference Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR: Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006, 24: 4692-4698. 10.1200/JCO.2006.06.7801.CrossRefPubMed Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR: Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006, 24: 4692-4698. 10.1200/JCO.2006.06.7801.CrossRefPubMed
50.
go back to reference Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K: PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007, 8: 797-805. 10.1016/S1470-2045(07)70244-9.CrossRefPubMed Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K: PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007, 8: 797-805. 10.1016/S1470-2045(07)70244-9.CrossRefPubMed
51.
go back to reference Ott K, Herrmann K, Krause BJ, Lordick F: The value of PET imaging in patients with localized gastroesophageal cancer. Gastrointest Cancer Res. 2008, 2: 287-294.PubMedCentralPubMed Ott K, Herrmann K, Krause BJ, Lordick F: The value of PET imaging in patients with localized gastroesophageal cancer. Gastrointest Cancer Res. 2008, 2: 287-294.PubMedCentralPubMed
52.
go back to reference zum Buschenfelde CM, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, Ott K, Ebert M, Zimmermann F, Friess H: (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med. 2011, 52: 1189-1196. 10.2967/jnumed.110.085803.CrossRefPubMed zum Buschenfelde CM, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, Ott K, Ebert M, Zimmermann F, Friess H: (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med. 2011, 52: 1189-1196. 10.2967/jnumed.110.085803.CrossRefPubMed
55.
go back to reference Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, Lordick F, Weichert W, Abel U, Debus J: Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg imaging program in cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. BMC Cancer. 2011, 11: 266-10.1186/1471-2407-11-266.PubMedCentralCrossRefPubMed Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, Lordick F, Weichert W, Abel U, Debus J: Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg imaging program in cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. BMC Cancer. 2011, 11: 266-10.1186/1471-2407-11-266.PubMedCentralCrossRefPubMed
56.
go back to reference Ku GY KD, Strong VE, Schöder H, Janjigian YY, Shah MA, Coit DG, Brennan MF, Capanu M, Ilson DH: Preoperative chemotherapy plus bevacizumab with early salvage therapy based on FDG-PET response in locally advanced gastroesophageal junction and gastric adenocarcinoma. J Clin Oncol. 2013, 31 (suppl): abstr 4101- Ku GY KD, Strong VE, Schöder H, Janjigian YY, Shah MA, Coit DG, Brennan MF, Capanu M, Ilson DH: Preoperative chemotherapy plus bevacizumab with early salvage therapy based on FDG-PET response in locally advanced gastroesophageal junction and gastric adenocarcinoma. J Clin Oncol. 2013, 31 (suppl): abstr 4101-
57.
go back to reference Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Konigsrainer A: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009, 27: 851-856. 10.1200/JCO.2008.17.0506.CrossRefPubMed Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Konigsrainer A: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009, 27: 851-856. 10.1200/JCO.2008.17.0506.CrossRefPubMed
58.
go back to reference Alberts SR, Soori GS, Shi Q, Wigle DA, Sticca RP, Miller RC, Leenstra JL, Peller PJ, Wu TT, Yoon HH, Drevyanko TF, Ko S, Mattar BI, Nikcevich DA, Behrens RJ, Khalil MF, Kim GP: Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849 [Abstract]. J Clin Oncol. 2013, 31: suppl; abstr 4026 Alberts SR, Soori GS, Shi Q, Wigle DA, Sticca RP, Miller RC, Leenstra JL, Peller PJ, Wu TT, Yoon HH, Drevyanko TF, Ko S, Mattar BI, Nikcevich DA, Behrens RJ, Khalil MF, Kim GP: Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849 [Abstract]. J Clin Oncol. 2013, 31: suppl; abstr 4026
59.
go back to reference Seto Y, Chin K, Gomi K, Kozuka T, Fukuda T, Yamada K, Matsubara T, Tokunaga M, Kato Y, Yafune A, Yamaguchi T: Treatment of thoracic esophageal carcinoma invading adjacent structures. Cancer Sci. 2007, 98: 937-942. 10.1111/j.1349-7006.2007.00479.x.CrossRefPubMed Seto Y, Chin K, Gomi K, Kozuka T, Fukuda T, Yamada K, Matsubara T, Tokunaga M, Kato Y, Yafune A, Yamaguchi T: Treatment of thoracic esophageal carcinoma invading adjacent structures. Cancer Sci. 2007, 98: 937-942. 10.1111/j.1349-7006.2007.00479.x.CrossRefPubMed
60.
go back to reference Reynolds JV: Randomised Clinical Trial of Neoadjuvant and Adjuvant Chemotherapy (MAGIC Regimen) vs. Neoadjuvant Chemoradiation (CROSS Protocol) in Adenocarcinoma of the Oesophagus and Oesophago-gastric Junction. 2012, US National Library of Medicine, ClinicalTrials.gov [online]. http://clinicaltrials.gov/show/NCT01726452 Reynolds JV: Randomised Clinical Trial of Neoadjuvant and Adjuvant Chemotherapy (MAGIC Regimen) vs. Neoadjuvant Chemoradiation (CROSS Protocol) in Adenocarcinoma of the Oesophagus and Oesophago-gastric Junction. 2012, US National Library of Medicine, ClinicalTrials.gov [online]. http://​clinicaltrials.​gov/​show/​NCT01726452
63.
go back to reference Crosby THC, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, Bridgewater JA, Geh I, Cunningham D, Maughan T, Griffiths G: SCOPE 1: a phase II/III trial of chemoradiotherapy in esophageal cancer plus or minus cetuximab. J Clin Oncol. 2012, 30 (suppl 34): abstr LBA3- Crosby THC, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, Bridgewater JA, Geh I, Cunningham D, Maughan T, Griffiths G: SCOPE 1: a phase II/III trial of chemoradiotherapy in esophageal cancer plus or minus cetuximab. J Clin Oncol. 2012, 30 (suppl 34): abstr LBA3-
64.
go back to reference Hurt CN, Nixon LS, Griffiths GO, Al-Mokhtar R, Gollins S, Staffurth JN, Phillips CJ, Blazeby JM, Crosby TD: SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer. 2011, 11: 466-10.1186/1471-2407-11-466.PubMedCentralCrossRefPubMed Hurt CN, Nixon LS, Griffiths GO, Al-Mokhtar R, Gollins S, Staffurth JN, Phillips CJ, Blazeby JM, Crosby TD: SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer. 2011, 11: 466-10.1186/1471-2407-11-466.PubMedCentralCrossRefPubMed
65.
go back to reference Power DG, Ilson DH: Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Ther Adv Med Oncol. 2009, 1: 145-165. 10.1177/1758834009347323.PubMedCentralCrossRefPubMed Power DG, Ilson DH: Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Ther Adv Med Oncol. 2009, 1: 145-165. 10.1177/1758834009347323.PubMedCentralCrossRefPubMed
66.
go back to reference Meza-Junco J, Au HJ, Sawyer MB: Trastuzumab for gastric cancer. Expert Opin Biol Ther. 2009, 9: 1543-1551. 10.1517/14712590903439702.CrossRefPubMed Meza-Junco J, Au HJ, Sawyer MB: Trastuzumab for gastric cancer. Expert Opin Biol Ther. 2009, 9: 1543-1551. 10.1517/14712590903439702.CrossRefPubMed
70.
go back to reference Crosby T, Hurt C, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, Bridgewater JA, Geh I, Cunningham D, Maughan T, Griffiths G: Erbitux Add-On Falls Short in Esophageal Ca [Abstract]. J Clin Oncol. 2012, 30: suppl 34; abstr LBA3 Crosby T, Hurt C, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, Bridgewater JA, Geh I, Cunningham D, Maughan T, Griffiths G: Erbitux Add-On Falls Short in Esophageal Ca [Abstract]. J Clin Oncol. 2012, 30: suppl 34; abstr LBA3
76.
go back to reference Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY: Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol. 2013, 24: 1754-1761. 10.1093/annonc/mdt106.PubMedCentralCrossRefPubMed Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY: Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol. 2013, 24: 1754-1761. 10.1093/annonc/mdt106.PubMedCentralCrossRefPubMed
78.
go back to reference Stricker T, Catenacci DV, Seiwert TY: Molecular profiling of cancer–the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin Oncol. 2011, 38: 173-185. 10.1053/j.seminoncol.2011.01.013.CrossRefPubMed Stricker T, Catenacci DV, Seiwert TY: Molecular profiling of cancer–the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin Oncol. 2011, 38: 173-185. 10.1053/j.seminoncol.2011.01.013.CrossRefPubMed
Metadata
Title
Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care
Authors
Amikar Sehdev
Daniel VT Catenacci
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2013
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-6-66

Other articles of this Issue 1/2013

Journal of Hematology & Oncology 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine